New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET

FMW Media Works Corp
FMW Media Works Corp

In This Article:

New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET

Episode 583: 1). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). OriginClear, Inc. (OTC: OCLN) ($OCLN) 3). Sustainable Green Team, Ltd. (OTC: SGTM) ($SGTM) 4). Hapbee Technologies, Inc. (OTCQB: HAPBF) (TSXV: HAPB) (FSE: HA1) ($HAPBF) 5). Sekur Private Data Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®) -www.newtothestreet.com
Episode 583: 1). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). OriginClear, Inc. (OTC: OCLN) ($OCLN) 3). Sustainable Green Team, Ltd. (OTC: SGTM) ($SGTM) 4). Hapbee Technologies, Inc. (OTCQB: HAPBF) (TSXV: HAPB) (FSE: HA1) ($HAPBF) 5). Sekur Private Data Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur?) -www.newtothestreet.com

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its national TV business show, Episode 583, airing on Bloomberg TV as sponsored programming, Saturday, August 10, 2024, at 6:30 PM ET.

New to The Street's TV Episode 583 will air the following five (5) riveting business interviews:

1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) David Luci, President/CEO.

2). Water Company – OriginClear, Inc.'s (OTC: OCLN) ($OCLN) Riggs Eckelberry, CEO, Ken Berenger, Executive Vice-President, and Kevin Harrington, Businessman and Panel Member of “Shark Tank” TV show.

3). Sustainable Solutions - The Sustainable Green Team, Ltd.'s (OTC: SGTM) ($SGTM) Tony Raynor, CEO and Founder.

4). Digital Wellness – Hapbee Technologies, Inc.'s (OTCQB: HAPBF) (TSXV: HAPB) (FSE: HA1) ($HAPBF) Yona Shtern, CEO/Founder, and Heather Thomson, Business Development Advisor.

5). "Sekur Privacy & Sekur Security – The Weekly Hack” segment with internet privacy expert Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur?).

Episode 583

From the Nasdaq MarketSite Studio, New to The Street's TV Host Jane King talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) ("Company"), a late-stage biopharmaceutical company that publicly trades on the NASDAQ market. ACXP is developing a new class of small molecular antibiotics for the most common life-threatening bacterial infections. Recently, the Company completed its FDA Phase 2 clinical trials on its Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Management is now meeting with the FDA regarding the steps necessary to complete the Phase 3 clinical trial on the drug. Concurrently, ACXP is meeting with the FDA on the manufacturing processes of the drug, which needs to meet the government’s standards. Management remains confident that Ibezapolstat can be manufactured and inventoried before the conclusion of 2024. The United States Patent and Trademark Office (USPTO) has issued a patent because the drug can, in treated patients, maintain and restore microbiome bacteria. Most pharmaceuticals destroy the gut’s microbiome bacteria which is the major cause of diseases and reinfections, typically from competitor drugs for CDI. The issued patent remains valid until June 2042. The Company is working globally with several entities seeking partnerships and other collaborations on non-dilutive financing arrangements for the funding needs of the FDA Phase 3. The objective is to get funded without using ACXP’s stock, which will not dilute shareholders’ value. David started a program to work with college students, being a mentor to assist students in bringing their scientific ideas to market. With the FDA and USPTO continuing to provide timely approvals, the Company has shown that its Ibezapolstat drug effectively treats CDI with no reinfections. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. - https://www.acurxpharma.com/.